Clinical Trials Browser

Phase 2 × Interventional × Metastatic Castration-Resistant Prostate Cancer Patients × Clear all

NCT03643107 2025-01-23

Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Phase 2 Completed

Metastatic Castration-Resistant Prostate Cancer Patients